company background image
6887

Hangzhou Biotest BiotechLtd SHSE:688767 Stock Report

Last Price

CN¥45.59

Market Cap

CN¥4.9b

7D

-8.9%

1Y

-27.8%

Updated

24 Sep, 2022

Data

Company Financials
688767 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends4/6

688767 Stock Overview

Hangzhou Biotest Biotech Co., LTD. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and equipment in China and Internationally.

Hangzhou Biotest BiotechLtd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hangzhou Biotest BiotechLtd
Historical stock prices
Current Share PriceCN¥45.59
52 Week HighCN¥152.50
52 Week LowCN¥45.00
Beta0
1 Month Change-17.81%
3 Month Change-29.54%
1 Year Change-27.75%
3 Year Changen/a
5 Year Changen/a
Change since IPO-40.89%

Recent News & Updates

Shareholder Returns

688767CN BiotechsCN Market
7D-8.9%-4.7%-1.9%
1Y-27.8%-35.5%-18.6%

Return vs Industry: 688767 exceeded the CN Biotechs industry which returned -35.5% over the past year.

Return vs Market: 688767 underperformed the CN Market which returned -18.6% over the past year.

Price Volatility

Is 688767's price volatile compared to industry and market?
688767 volatility
688767 Average Weekly Movement4.5%
Biotechs Industry Average Movement4.8%
Market Average Movement5.8%
10% most volatile stocks in CN Market9.3%
10% least volatile stocks in CN Market3.7%

Stable Share Price: 688767 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 688767's weekly volatility has decreased from 11% to 5% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008702n/ahttps://www.biotests.com.cn

Hangzhou Biotest Biotech Co., LTD. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and equipment in China and Internationally. It offers medical test products for fertility health, oncology, cardiology, inflammation, biochemistry, and various infectious diseases, as well as COVID-19 rapid tests, such as antibody and antigen testing kits; and urine and saliva drug, hair drug, and vitamin D rapid testing kits.

Hangzhou Biotest BiotechLtd Fundamentals Summary

How do Hangzhou Biotest BiotechLtd's earnings and revenue compare to its market cap?
688767 fundamental statistics
Market CapCN¥4.86b
Earnings (TTM)CN¥1.01b
Revenue (TTM)CN¥2.18b

4.8x

P/E Ratio

2.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
688767 income statement (TTM)
RevenueCN¥2.18b
Cost of RevenueCN¥908.05m
Gross ProfitCN¥1.28b
Other ExpensesCN¥266.34m
EarningsCN¥1.01b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)9.47
Gross Margin58.43%
Net Profit Margin46.23%
Debt/Equity Ratio0.008%

How did 688767 perform over the long term?

See historical performance and comparison

Dividends

6.6%

Current Dividend Yield

30%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 688767 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688767?

Other financial metrics that can be useful for relative valuation.

688767 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.2x
Enterprise Value/EBITDA2.5x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 688767's PE Ratio compare to its peers?

688767 PE Ratio vs Peers
The above table shows the PE ratio for 688767 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average14.1x
300485 Beijing Science Sun Pharmaceutical
9.5xn/aCN¥5.2b
300149 Chempartner Pharmatech
8.8xn/aCN¥4.8b
002880 Shenzhen Weiguang Biological Products
28.1xn/aCN¥5.7b
603387 Getein Biotech
10.2xn/aCN¥5.7b
688767 Hangzhou Biotest BiotechLtd
4.8xn/aCN¥4.9b

Price-To-Earnings vs Peers: 688767 is good value based on its Price-To-Earnings Ratio (4.8x) compared to the peer average (14.1x).


Price to Earnings Ratio vs Industry

How does 688767's PE Ratio compare vs other companies in the CN Biotechs Industry?

Price-To-Earnings vs Industry: 688767 is good value based on its Price-To-Earnings Ratio (4.8x) compared to the CN Biotechs industry average (29.6x)


Price to Earnings Ratio vs Fair Ratio

What is 688767's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688767 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio4.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 688767's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 688767 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688767 (CN¥45.59) is trading below our estimate of fair value (CN¥219.25)

Significantly Below Fair Value: 688767 is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Hangzhou Biotest BiotechLtd forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


26.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hangzhou Biotest BiotechLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine whether Hangzhou Biotest BiotechLtd is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.

Past Performance

How has Hangzhou Biotest BiotechLtd performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


48.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 688767 has a high level of non-cash earnings.

Growing Profit Margin: 688767's current net profit margins (46.2%) are higher than last year (45.9%).


Past Earnings Growth Analysis

Earnings Trend: 688767's earnings have grown significantly by 48% per year over the past 5 years.

Accelerating Growth: 688767's earnings growth over the past year (44%) is below its 5-year average (48% per year).

Earnings vs Industry: 688767 earnings growth over the past year (44%) exceeded the Biotechs industry 6.5%.


Return on Equity

High ROE: 688767's Return on Equity (39.9%) is considered high.


Discover strong past performing companies

Financial Health

How is Hangzhou Biotest BiotechLtd's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 688767's short term assets (CN¥2.5B) exceed its short term liabilities (CN¥430.3M).

Long Term Liabilities: 688767's short term assets (CN¥2.5B) exceed its long term liabilities (CN¥10.4M).


Debt to Equity History and Analysis

Debt Level: 688767 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if 688767's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 688767's debt is well covered by operating cash flow (484056.6%).

Interest Coverage: 688767 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Hangzhou Biotest BiotechLtd current dividend yield, its reliability and sustainability?

Dividend Score

4/6

Dividend Score 4/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


6.58%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 688767's dividend (6.58%) is higher than the bottom 25% of dividend payers in the CN market (0.52%).

High Dividend: 688767's dividend (6.58%) is in the top 25% of dividend payers in the CN market (2.1%)


Stability and Growth of Payments

Stable Dividend: Too early to tell whether 688767's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if 688767's dividend payments are increasing as they only just started paying a dividend.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (29.7%), 688767's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (44.7%), 688767's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Hangzhou Biotest BiotechLtd has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 70.98% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
23.34%
Hangzhou Tuokang Investment Co., Ltd.
24,896,000CN¥1.1b0%no data
20.46%
Yinlong Chen
21,824,000CN¥995.0m0%no data
11.25%
Hangzhou Kangyu Enterprise Management Consulting Partnership Enterprise (Limited Partnership)
12,000,000CN¥547.1m0%no data
5.63%
Qifu Li
6,000,000CN¥273.5m0%no data
3%
Yujie Chen
3,200,000CN¥145.9m0%no data
2.16%
Hangzhou Biotest Biotech Co.,Ltd., ESOP
2,304,000CN¥105.0m0%no data
2.1%
Shujiang Wu
2,240,000CN¥102.1m0%no data
2.1%
Hongmei Gao
2,240,000CN¥102.1m0%no data
0.23%
China International Capital Corporation Hong Kong Asset Management Limited
249,250CN¥11.4m0%0.07%
0.22%
Huatai Securities (Shanghai) Asset Management Co., Ltd.
234,056CN¥10.7m0%0.06%
0.14%
Beijing Tonghui Changfu Software Technology Co., Ltd.
154,024CN¥7.0m12.91%no data
0.063%
Van Eck Associates Corporation
66,750CN¥3.0m-26.67%no data
0.03%
E Fund Management Co., Ltd.
31,485CN¥1.4m-1.17%no data
0.028%
Penghua Fund Management Co. Ltd.
29,956CN¥1.4m0%no data
0.028%
Bosera Asset Management Co., Ltd.
29,468CN¥1.3m0%no data
0.026%
Dacheng Fund Management Company Limited
27,428CN¥1.3m0%no data
0.025%
China Asset Management Co., Ltd.
26,640CN¥1.2m0%no data
0.025%
Hua An Fund Management Co., Ltd.
26,416CN¥1.2m0%no data
0.025%
ICBC Credit Suisse Asset Management Co., Ltd.
26,275CN¥1.2m0%no data
0.022%
Harvest Fund Management Co., Ltd.
23,460CN¥1.1m0%no data
0.021%
GF Fund Management Co., Ltd.
21,948CN¥1.0m0%no data
0.017%
China Merchants Fund Management Co.,Ltd.
17,760CN¥809.7k0%no data
0.014%
Invesco Great Wall Fund Management Co. Ltd
14,922CN¥680.3k0%no data
0.012%
Wanjia Asset Management Co., Ltd.
13,320CN¥607.3k0%no data
0.012%
Yinhua Fund Management Co. Ltd.
13,320CN¥607.3k0%no data

Company Information

Hangzhou Biotest Biotech Co.,Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Hangzhou Biotest Biotech Co.,Ltd.
  • Ticker: 688767
  • Exchange: SHSE
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CN¥4.863b
  • Shares outstanding: 106.67m
  • Website: https://www.biotests.com.cn

Number of Employees


Location

  • Hangzhou Biotest Biotech Co.,Ltd.
  • No.17, Futai Road
  • Zhongtai Street
  • Hangzhou
  • Zhejiang Province
  • 311121
  • China


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
688767SHSE (Shanghai Stock Exchange)YesDomestic SharesCNCNYSep 2021

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/24 00:00
End of Day Share Price2022/09/23 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.